yahoo_financeOriginal article
Mirum Pharmaceuticals Says Livmarli Meets Primary Endpoint in Phase 3 Liver Disease Trial
Phase 3positiveLivmarliPositive
AI Analysis
Summary
Mirum Pharmaceuticals announced that Livmarli met its primary endpoint in a Phase 3 trial for liver disease. This positive trial result represents a significant milestone for the drug's development program.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
met primary endpoint
Importance:7/10
Sentiment:
0.80
Phase 3 dataprimary endpoint metliver diseaseclinical trial
Related Companies
Read the original article
Published by yahoo_finance on October 12, 2026 12:43 PM